Novartis experimental prostate cancer drug gets FDA breakthrough designation
June 18 2021, 08:00
Novartis announced on Wednesday that the FDA granted Breakthrough Therapy designation to an experimental therapy that targets advanced castration-resistant prostate cancer.
Novartis announced on Wednesday that the FDA granted Breakthrough Therapy designation to an experimental therapy that targets advanced castration-resistant prostate cancer.
Source:
FOX News